User menu

Database for Serial Magnetic-resonance-imaging in Multiple-sclerosis

Bibliographic reference Barkhof, F. ; Thompson, AJ. ; Kappos, L. ; Nauta, JJP. ; Yousri, T. ; et. al. Database for Serial Magnetic-resonance-imaging in Multiple-sclerosis. In: Neuroradiology : a journal devoted to neuroimaging and interventional neuroradiology, Vol. 35, no. 5, p. 362-366 (1993)
Permanent URL http://hdl.handle.net/2078.1/49727
  1. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action guidelines. J Neurol Neurosurg Psychiatry 54:683?688
  2. Poser CM, Paty DW, Scheinberg L, et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227?231
  3. Thompson AJ, Kermode AG, Wicks D, et al (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53?62
  4. Thompson AJ, Miller D, Youl B, et al (1992) Serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis of varying disease duration. Neurology 42:60?63
  5. Barkhof F, Hommes OR, Scheltens P, Valk J (1991) Quantitative MRI changes in gadolinium-DTPA enhancement after highdose intravenous methylprednisolone in multiple sclerosis. Neurology 41:1219?1222
  6. Burham JA, Wright RR, Dreisbach J, Murray RS (1991) The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 41:1349?1354
  7. Miller DH, Thompson AJ, Morrissey SP, et al (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55 (in press)
  8. Hawkins CP, Munro PMG, MacKenzie F, et al (1990) Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 113: 365?378
  9. Katz D, Taubenberger J, Raine C, McFarlin D, McFarland H (1990) Gadolinium-enhancing lesions on magnetic resonance imaging: neuropathological findings. Ann Neurol 28:243
  10. Kuharik MA, Edwards MK, Farlow MR, et al (1988) Gd-enhanced MR imaging of acute and chronic experimental dymyelinating lesions. AJNR 9:643?648
  11. Harris JO, Frank JA, Patronas N, McFarlan DE, McFarland HF (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis:implications for clinical trials. Ann Neurol 29:548?555
  12. Bastianello S, Pozzili C, Bernardi S, et al (1990) Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 40:591?595
  13. Miller DH, Rudge P, Johnson G, et al (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927?939
  14. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, González-Scarano F (1988) Multiple sclerosis: serial study of a gadolinium-enhanced MR imaging. Radiology 169: 117?122
  15. Barkhof F, Scheltens P, Frequin STFM, Nauta JJP, Tas MW, Valk J, Hommes OR (1992) Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR 159:1041?1047
  16. Kermode AG, Thompson AJ, Tofts P, et al (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions multiple sclerosis. Brain 113:1477?1489
  17. Larsson HBW, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB (1990) Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Res Med 16:117?131
  18. Paty DW (1991) Multiple sclerosis with an emphasis on MR imaging. In: Appel SH (ed) Current neurology. Mosby, St. Louis, pp 169?198
  19. Wicks D, Tofts PS, Miller DH, et al (1992) Volume measurements of multiple sclerosis lesions with magnetic resonance imaging: a preliminary study. Neuroradiology 34:475?479
  20. Truyen L, Gheuens J, Parizel PM, Van de Vyver FL, Martin JJ (1991) Long term follow-up of multiple sclerosis by standardized, non-contrast-enhanced magnetic resonance imaging. J Neurol Sci 106:35?40
  21. Paty DW (1988) Trial measures in multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials. Neurology 38 [Suppl 2]:82?83
  22. Paty DW, Oger JJF, Kastrukoff LF, et al (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180?185
  23. Uhlenbrock D, Seidel D, Gehlen W, et al (1988) MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potentials. AJNR 9:59?67
  24. Ormerod IEC, Miller DH, McDonald WI, et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological syndromes: a quantitative study. Brain 110: 1579?1616
  25. Isaac C., B. Li D. K., Genton M., Jardine C., Grochowski E., Palmer M., Kastrukoff L. F., Oger J., Paty D. W., Multiple sclerosis: A serial study using MRI in relapsing patients, 10.1212/wnl.38.10.1511
  26. Willoughby EW, Grochowski E, Li DKB, et al (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 25:43?49
  27. Koopmans RA, Li DKB, Oger JJF, et al (1989) Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 26:248?256
  28. Kappos L, Städt D, Ratzka M, et al (1988) Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 30:299?302
  29. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), 10.1212/wnl.33.11.1444
  30. Francis D. A., Bain P., Swan A. V., Hughes R. A. C., An Assessment of Disability Rating Scales Used in Multiple Sclerosis, 10.1001/archneur.1991.00530150067020
  31. Noseworthy J. H., Vandervoort M. K., Wong C. J., Ebers G. C., Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial, 10.1212/wnl.40.6.971